What is CAR T-Cell Therapy? | Dana-Farber Cancer Institute

Mastering CAR-T Cell Therapy in R/R Large B-Cell Lymphoma: Adverse Event ManagementПодробнее

Early findings from the CAR-PRISM trial of cilta-cel in high-risk smoldering myelomaПодробнее

New therapy helps keep patients cancer-free longerПодробнее

First results of CAR-PRISM: early safety and efficacy of CAR-T in high-risk smoldering myelomaПодробнее

2024 Mid-Year Myeloma Review with Paul Richardson, MD, Dana Farber Cancer InstituteПодробнее

IWWM-12: Latest updates and clinical developments in novel/emerging therapiesПодробнее

Cell Manipulation Core Facility at Dana-Farber Cancer InstituteПодробнее

Updated safety and efficacy of BMS-986393 in patients with R/R myeloma and 1-3 prior LOTПодробнее

Promising Results for Odronextamab in Post CAR T Patients with DLBCL | Jennifer Crombie, MD | #ASH24Подробнее

NOW Program Educational Webinars: Targeted Therapy Trials for GliomaПодробнее

Advances being made in high-risk smoldering myeloma: ongoing trials & promising agentsПодробнее

Antigen loss in patients with myeloma receiving immunotherapyПодробнее

A single-cell RNA analysis of tumor and immune cells in asymptomatic and overt WMПодробнее

Immunotherapy and gut bacteria | Dana-Farber Cancer InstituteПодробнее

Amy Bessnow, MD, MPH, on Lymphoma Treatment | Dana-Farber Cancer InstituteПодробнее

Managing Cellular Therapies at Dana-Farber's Cell Manipulation Core FacilityПодробнее

Immunotherapies in the future treatment landscape for Waldenström's macroglobulinemiaПодробнее

Frederick Locke, MD with Natasha Kekre, MD and Rizwan Romee, MD at Cell Coast Conference 2024Подробнее

How do I treat patients with RRMM after failure of BCMA-targeted therapies?Подробнее

CAR-E: PREVENTING RELAPSE AFTER CAR T-CELL THERAPYПодробнее